Practices

Pharma IP advisory work

Capabilities of IPEG in Pharmaceutical Lifecycle Management (LCM)


With new product pipelines often failing to deliver the blockbuster drugs needed to revitalize product portfolios, innovative pharmaceutical companies are increasingly relying on LCM of older brands to boost sales. Expert and state-of the-art advice on intellectual property management is an essential component of LCM.

  • Creation of IP strategies for pharmaceutical brands, optimizing valid useful patent scope and sequencing to ensure strong and long-lasting protection of brand exclusivity
  • Evaluation of patent portfolios protecting pharmaceutical brands; identification of weaknesses and design of improvement strategies
  • Competitor IP analyses
  • FTO analyses
  • IP Litigation support
  • Evaluation of probability of success in patent infringement situations prior to commencing litigation; design of litigation strategies
  • Identification of third-party patents relating to pharmaceutical brands; analysis of potential impact of these patents on brand lifecycle performance
  • Use of non-patent IP elements in protecting brand franchises (e.g. trademarkes, design rights, copyright)
  • Financial effect/risk analysis of proprietary to generic shift